Tisagenlecleucel not checked

Novartis · CTL019

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
6 active
17 in total · 7 in the EU
Targets
 

What this is

How it works
A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
How it’s given
“A single intravenous (i.v.) infusion of CAR-positive viable T cells.”In the company’s words, NCT04094311 on ClinicalTrials.gov
Tested for
B-cell Acute Lymphoblastic Leukemia (2 trials), Diffuse Large B-cell Lymphoma, Follicular Lymphoma (FL)
Main trialPhase 3
“This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.”In the company’s words, NCT04094311 on ClinicalTrials.gov
Other names
CTL019

Other drugs for B-cell Acute Lymphoblastic Leukemia

All 31 drugs for B-cell Acute Lymphoblastic Leukemia

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Mar 2027 Study of Out of Specification for Tisagenlecleucel
Phase 3Active, not recruiting 25 Jul 2028 A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Phase 2Active, not recruiting 19 Oct 2027 Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Phase 3Completed 13 Oct 2020 Phase III B in Acute Lymphoblastic Leukemia
Phase 2Completed 21 Jan 2020 Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Phase 2Completed 24 Nov 2020 Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Phase 2Completed 27 Jul 2021 Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Phase 2Terminated 19 Oct 2021 Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Phase 2Withdrawn 31 Oct 2022 Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Phase 2Withdrawn 30 Nov 2022 Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
Phase 2Completed 22 Dec 2022 Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Phase 1Completed 20 Jul 2021 Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Phase 1Terminated 1 Nov 2021 Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Phase 3Authorised not given Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-CellTherapy
Phase 1/2Authorised not given CAPTIRALL _ Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence
Phase 4Authorised not given Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study
Phase 1/2Halted not given Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tisagenlecleucel

Following is part of Solo: you see every change to Tisagenlecleucel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in